Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Arginine PCA, also known as arginine pidolate, is the salt formed by the amino acid L-arginine and L-pyroglutamic acid (pidolic acid). It is a multifunctional compound widely utilized in the cosmetic industry as a humectant and skin-conditioning agent, as both of its components are natural constituents of the skin's Natural Moisturizing Factor (NMF). Beyond its topical applications, Arginine PCA is used as a dietary supplement and a pharmaceutical agent, particularly in Europe, to address conditions such as physical and mental fatigue (asthenia). The compound provides a bioavailable source of L-arginine, which serves as a precursor for nitric oxide synthesis and urea cycle metabolism, and L-pyroglutamic acid, which is involved in the gamma-glutamyl cycle and has been studied for potential cognitive-enhancing effects. In clinical settings, it has been investigated for its ability to stimulate the release of growth hormone and improve metabolic recovery after exercise.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on arginine pidolate.